Merus Announces Re-Election of Directors
March 21 2017 - 6:19PM
PR Newswire (Canada)
TORONTO, March 21, 2017 /CNW/ - Merus Labs
International Inc. ("Merus" or the "Company") [TSX:
MSL, NASDAQ: MSLI] reported today the results of its 2017 annual
general and special meeting of shareholders held on March 21, 2017.
All directors nominated, as listed in the Company's management
information circular dated February 15,
2017 (the "Information Circular"), were re-elected as
members of the board as follows:
Director
|
Votes
For(*)
|
%
For
|
Withheld
Votes(*)
|
%
|
Michael
Cloutier
|
55,014,419
|
99.70%
|
165,368
|
0.30%
|
Robert S.
Pollock
|
55,006,380
|
99.69%
|
173,407
|
0.31%
|
Timothy G.
Sorensen
|
54,994,235
|
99.66%
|
185,552
|
0.34%
|
David D.
Guebert
|
55,018,949
|
99.71%
|
160,838
|
0.29%
|
Theresa
Firestone
|
55,018,300
|
99.71%
|
161,487
|
0.29%
|
Barry
Fishman
|
55,014,516
|
99.70%
|
165,271
|
0.30%
|
Robert
Bloch
|
55,001,680
|
99.68%
|
178,107
|
0.32%
|
(*) Reflects votes represented by
proxy
In addition, shareholders of the Company approved:
- the appointment of MNP LLP, Chartered Accountants, as the
auditor of Merus to hold office until the next annual meeting of
shareholders,
- the amendments to the Company's stock option plan announced on
March 13, 2017,
- the continuation of the Company's stock option plan for an
additional three year term, and
- the amendments to the Company's articles, as described in the
Information Circular, by special resolution.
About Merus Labs
Merus Labs is a specialty pharmaceutical company focused on
acquiring and optimizing established and growth products. The
Company leverages its expertise and commercial platform in
Europe, Canada and select other markets to deliver
value.
SOURCE Merus Labs Inc.
Copyright 2017 Canada NewsWire